Enterprise value to EBIT forward of CVRx, Inc. – NASDAQ:CVRX
The article focuses on the enterprise value to EBIT forward for CVRx, Inc. (NASDAQ: CVRX). It presents a snapshot of the company's financial data on TradingView, indicating that the market is closed at the time of viewing. The content primarily highlights where to find this financial metric within the TradingView platform for CVRx, Inc.
CVRX,INVA Volatility & Greeks
This article provides a detailed financial overview of two companies, CVRx Inc. (CVRX) and Innoviva Inc. (INVA), including their stock performance, market capitalization, key financial ratios, and analyst recommendations. It lists various metrics such as volatility, EPS, sales growth, insider ownership, and institutional ownership for both healthcare companies. The data offers a snapshot of their current financial health and market position.
CVRx shares rise on CMS inclusion for Barostim implant procedure
CVRx shares increased following the Centers for Medicare and Medicaid Services' decision to include the Barostim implant procedure in its inpatient hospital prospective payment system. This inclusion means that patients undergoing Barostim implantation will be eligible for Medicare coverage. The news positively impacted investor confidence, leading to a rise in the company's stock.
Enterprise value to revenue forward of CVRx, Inc. – NASDAQ:CVRX
The article presents information regarding the enterprise value to forward revenue for CVRx, Inc. (NASDAQ: CVRX). It is a finance-related snippet from TradingView, focusing on the company's financials within the health technology sector. The content appears to be a stub or a section of a larger financial data presentation, without detailed analysis.
Price to earnings forward of CVRx, Inc. – NASDAQ:CVRX
The article provides information regarding the forward price-to-earnings ratio for CVRx, Inc. (NASDAQ: CVRX) within the TradingView platform. It shows the navigation path to access this financial data and emphasizes that the market was closed with no trades at the time of viewing.
Price to book forward of CVRx, Inc. – NASDAQ:CVRX
This article displays information regarding the "Price to book forward" metric for CVRx, Inc. (NASDAQ: CVRX) on TradingView. It indicates that the data is provided by human input and is available in English. The page is part of TradingView's financial data section for CVRx, Inc.
CVRx, Inc. Actuals & Estimates (NASDAQ:CVRX)
This article provides an overview of CVRx, Inc. (NASDAQ:CVRX) stock performance, financial actuals, and analyst estimates. It highlights the current stock price, recent changes, market capitalization, and future earnings expectations, along with historical data like all-time highs and lows.
CVRX Forecast — Price Target — Prediction for 2027
The article provides a forecast for CVRx, Inc. (CVRX) stock, including analyst price targets and ratings. It details the company's current stock price, historical performance, and future revenue and earnings expectations, while also providing key financial metrics such as market capitalization and EBITDA.
(CVRX) Movement as an Input in Quant Signal Sets
This article from Stock Traders Daily analyzes CVRX, highlighting a strong near-term sentiment that could challenge persistent mid and long-term weakness. It identifies an exceptional 187.0:1 risk-reward setup, targeting a substantial gain with minimal risk. The analysis provides specific institutional trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
CVRx Inc (CVRX) Institutional Confidence
The article analyzes the institutional confidence in CVRx Inc (CVRX), revealing a current institutional shareholding score of 5.00, placing it 109th out of 203 in its industry. The institutional shareholding proportion decreased by 19.00% quarter-over-quarter to 65.53%. Bill Nygren | OAKMX is the largest institutional shareholder, despite a significant decrease in holdings.
CVRx Inc (CVRX) Stock Forecast & Analyst Ratings
This article provides a stock forecast and analyst ratings for CVRx Inc (CVRX). It likely includes insights into the company's financial performance, market position, and future outlook based on expert analysis, offering guidance for potential investors or current shareholders.
CVRx Inc (CVRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of CVRx Inc (CVRX), detailing its current price momentum score, support and resistance levels, and various technical indicators and moving averages. The analysis suggests the stock is currently trading between a resistance level of 6.00 and a support level of 4.34, suitable for range-bound swing trading. Based on the indicators, the overall signal for CVRx Inc is "Sell," particularly from the moving averages.
CVRx Inc (CVRX) Financial Health: Profitability & Balance Sheet Analysis
CVRx Inc (CVRX) currently holds a financial score of 6.70, placing it 140th out of 203 companies in the Healthcare Equipment & Supplies industry. The company's financial status is stable, though its operating efficiency is noted as low. In its latest quarter, CVRx Inc reported a 19.61% year-over-year revenue increase to $14.77 million, with net profit growing by 4.69% over the same period.
CVRx Inc (CVRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for CVRx Inc (CVRX), showing its revenue by region. As of the last update on April 6, CVRx Inc's total revenue was $51.88 million from the US and $4.77 million from Europe, making up 91.58% and 8.42% of its revenue respectively. The article notes that relevant data for segment-wise revenue has not yet been disclosed by the company.
CVRX: CFO transition, expanded clinical trials, and improved reimbursement drive growth and adoption
CVRx is undergoing a CFO transition and is focused on expanding its Barostim therapy, which targets a significant U.S. market. The company aims to triple its market opportunity through ongoing clinical trials and expects accelerated adoption and improved financial performance due to enhanced reimbursement and strong Q1 growth. This information is based on the Goldman Sachs 47th Annual Global Healthcare Conference 2026 audio transcript.
Press Release: CVRx Announces Chief Financial Officer Transition
CVRx announced a Chief Financial Officer transition. Jared Eliot will be taking over as the new CFO, replacing Paula Kelley. This transition is part of the company's ongoing management strategy.
Craig-Hallum Maintains CVRx Inc(CVRX.US) With Buy Rating
Craig-Hallum has reiterated its Buy rating on CVRx Inc (CVRX.US). The article does not provide further details regarding the rationale behind this rating or any financial analysis.
CVRx CFO Jared Oasheim to step down after decade with company By Investing.com
CVRx, Inc. announced that CFO Jared Oasheim will be stepping down from his role after joining the company in 2015. He will remain an advisor until February 2027 while CVRx searches for a successor to lead its finance organization. The company, which develops neuromodulation devices for cardiovascular patients, recently exceeded Q1 2026 earnings expectations and secured Medicare Advantage coverage for its Barostim therapy from Humana.
CVRx Chief Financial Officer Jared Oasheim Leaving
CVRx announced that Chief Financial Officer Jared Oasheim will be leaving the company on July 5, 2024, to pursue another opportunity. The company has initiated a search for his successor. Oasheim's departure is not due to any disagreement with CVRx's accounting principles or financial disclosures.
CVRx CFO Jared Oasheim to step down after decade with company
Jared Oasheim, CFO of CVRx, Inc. (NASDAQ:CVRX), will be stepping down from his position after a decade with the company to pursue other professional opportunities. Oasheim, who played a key role in the company's IPO and establishing its financial organization, will remain until a successor is found and will serve as an advisor until February 2027. CVRx, a medical device company with a market capitalization of $143 million, is searching for a new CFO and continues to see positive developments for its Barostim device, including strong Q1 2026 earnings and Medicare Advantage coverage from Humana.
CVRx Announces Chief Financial Officer Transition
CVRx, Inc. (NASDAQ: CVRX) announced that Jared Oasheim, its Chief Financial Officer, will be stepping down to pursue other professional opportunities. Mr. Oasheim will remain with the company until a successor is appointed and act as an advisor until February 2027 to ensure a smooth transition. The company is initiating a search for his replacement and acknowledged his significant contributions, including leading CVRx through its IPO.
CVRx CFO Jared Oasheim to Resign, Will Stay Through Transition and Serve as Consultant
Jared Oasheim, CFO of CVRx, has announced his resignation to pursue other professional opportunities but will remain with the company through a transition period and serve as a paid consultant. His resignation notice was dated June 7, 2026, and he will continue as CFO until a successor is found, with a full-time employment period extending until at least August 31, 2026, followed by consulting services through February 2027. Oasheim will be eligible for his 2026 cash incentive, receive cash payments totaling $262,000, and be compensated at $245/hour for consulting.
[8-K] CVRx, Inc. Reports Material Event
CVRx, Inc. announced that its Chief Financial Officer, Jared Oasheim, will resign to pursue other professional opportunities. He will remain CFO until a successor is found and will then serve as a consultant through February 2027 to ensure a smooth transition. The company has detailed an Employment Transition Agreement, including compensation for Oasheim's assistance and an extended stock option exercise period.
Medical device firm CVRx plans CFO change, keeps him through Feb. 2027
CVRx announced that CFO Jared Oasheim will step down to pursue new opportunities but will remain with the company until a successor is appointed and will advise through February 2027. The company has initiated a search for a new CFO and highlighted Oasheim's contributions, including leading the IPO. CVRx also confirmed that current CEO Kevin Hykes and Oasheim will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026.
CVRx Announces Chief Financial Officer Transition
CVRx, Inc. announced that CFO Jared Oasheim will be stepping down to pursue other professional opportunities but will remain with the company during the transition and as an advisor through February 2027. CEO Kevin Hykes praised Oasheim's contributions, including leading the company's IPO and building its finance organization. CVRx has initiated a search for a new Chief Financial Officer.
William Blair Maintains CVRx Inc(CVRX.US) With Buy Rating
William Blair has reiterated its "Buy" rating for CVRx Inc (CVRX.US). This continued endorsement from the investment bank suggests a positive outlook on the company's stock performance. Investors will likely view this as a sign of confidence in CVRx's current strategy and future prospects.
CVRx, Inc. (CVRX) director receives new share and option grants
CVRx, Inc. director Mudit K. Jain received new equity compensation, including 8,720 shares of Common Stock and a stock option for 11,182 shares with an exercise price of $5.43 per share. These grants increase his direct holdings to 14,370 shares, and the stock option vests by June 1, 2027, or the company's 2027 annual stockholder meeting. Jain also indirectly holds 980,183 shares through Treo Ventures I, L.P., where he is the general partner.
CVRx (CVRX) director receives new share and stock option awards
CVRx, Inc. director Kevin J. Ballinger has been granted equity compensation, including 8,720 shares of common stock and a stock option for 11,182 shares at an exercise price of $5.43 per share. These awards represent compensation rather than open-market transactions, vesting on the earlier of June 1, 2027, or the company's 2027 annual meeting. Following these grants, Ballinger directly holds 8,720 common shares and the stock option.
CVRx (NASDAQ: CVRX) director Nielsen awarded shares and 11,182-share option
CVRx, Inc. director Kirk G. Nielsen was awarded 8,720 shares of common stock at no cost and an option for 11,182 shares with an exercise price of $5.43, expiring in June 2036. The option vests by June 1, 2027, or the company’s 2027 annual meeting. Nielsen also indirectly holds 1,910,134 common shares through Vensana Capital I, L.P., where he shares voting and dispositive power.
William Blair Maintains CVRx Inc(CVRX.US) With Buy Rating
William Blair has reiterated its Buy rating for CVRx Inc (CVRX.US). Further details on the reasons for maintaining this rating or any specific financial analysis are not provided in this brief update.
[Form 4] CVRx, Inc. Insider Trading Activity
CVRx, Inc. director Joseph P. Slattery reported receiving compensation-related equity grants, including 8,720 shares of Common Stock and a stock option for 11,182 shares. The stock option has an exercise price of $5.43 and vests on the earlier of June 1, 2027, or the company’s 2027 annual meeting. After these grants, Slattery directly holds 39,365 Common shares, with these transactions classified as awards rather than open-market trades.
[Form 3] CVRx, Inc. Initial Statement of Beneficial Ownership
CVRx, Inc. director Michael D. Dale filed a Form 3, an initial statement of beneficial ownership, with the SEC. The filing indicates Dale's position as a director but reports no current transactions or beneficial ownership of CVRx stock. This Form 3 provides transparency regarding new affiliations between company insiders and the firm.
Martha Shadan of CVRx, Inc. (CVRX) receives stock and option grants
CVRx, Inc. director Martha Shadan received 8,720 shares of Common Stock as a no-cost grant and options for 11,182 shares with an exercise price of $5.43, expiring in 2036. These awards are compensation-related and increase her direct holdings in the company, with the options vesting on the earlier of June 1, 2027, or the company's 2027 annual meeting. The transaction is identified as a grant/award and not an open-market purchase or sale.
Why (CVRX) Price Action Is Critical for Tactical Trading
Cvrx Inc. (NASDAQ: CVRX) is showing weak near and mid-term sentiment, though its long-term outlook is neutral. The stock is currently testing support, and if it holds, resistance is expected next. Institutional trading strategies, including position trading, momentum breakout, and risk hedging, have been generated by AI models with a notable 99.5:1 risk-reward setup targeting a 36.6% gain.
CVRX: Barostim drives heart failure innovation with strong clinical results and expanding market access
CVRX's Barostim device targets a large, underserved heart failure market, showing significant improvements in quality of life and strong clinical evidence. The company is poised for growth due to regulatory advancements and expanded reimbursement, including new Medicare Advantage coverage, with projected 2026 revenues of $63M–$67M.
CVRX News | CVRX INC (NASDAQ:CVRX)
The CVRX News page for CVRX Inc. (NASDAQ:CVRX) aggregates recent articles and press releases related to the company. Key updates include recent earnings reports, upcoming conference presentations, and news regarding Medicare coverage for its Barostim therapy, which positively impacted its stock. The company's stock performance and analyst insights are also briefly mentioned.
CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
CVRx, Inc., a medical device company specializing in neuromodulation solutions for cardiovascular diseases, announced its management team will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, at 8:00 a.m. ET. A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible for a limited time afterward. CVRx's flagship product, Barostim™, is an FDA-approved medical technology designed to improve heart failure symptoms through neuromodulation.
CVRx to Present at the William Blair 46th Annual Growth Stock Conference
CVRx, Inc. (NASDAQ: CVRX) announced it will participate in the upcoming William Blair 46th Annual Growth Stock Conference. CEO Nadim Yared and CFO Jayshree Seth will present and host one-on-one meetings at the event in Chicago. The presentation will be accessible via webcast on the company's investor relations website.
CVRx to present at William Blair Growth Stock Conference on June 2, 2026
CVRx, a medical device company, announced it will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026, in Chicago. The company will showcase its Barostim therapy, an FDA-approved device for heart failure. This presentation will offer insights into CVRx's commercial advancements and future prospects, with a live webcast available for investors.
CVRx to Present at the William Blair 46th Annual Growth Stock Conference
CVRx, Inc., a medical device company, announced that its management team will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026, at 10:40 a.m. CT. A live webcast and archived version of the presentation will be available on the company's investor relations website. CVRx focuses on neuromodulation solutions for cardiovascular diseases, with its Barostim™ therapy being FDA-approved for heart failure.
CVRx to Present at the William Blair 46th Annual Growth Stock Conference
CVRx, Inc. announced that its management team will present at the William Blair 46th Annual Growth Stock Conference on June 2, 2026, at 10:40 a.m. CT. A live webcast and archive of the presentation will be available on the company's investor relations website. CVRx is a medical device company specializing in neuromodulation solutions for cardiovascular diseases, featuring Barostim™, an FDA-approved technology for heart failure patients.
CVRx marks 25th Barostim implant milestone at UNC Medical Center Chapel Hill
CVRx announced the 25th successful Barostim implant at UNC Medical Center in Chapel Hill, highlighting the collaborative efforts of the medical team. This milestone follows a 20% increase in CVRx's first-quarter revenue and the commencement of patient enrollment for its BENEFIT-HF clinical trial, underscoring the company's growth and contributions to cardiac care.
CVRx Inc stock (US12674F1003): Medtronic takeover bid puts heart-device specialist in the spotlight
Medtronic has made an all-cash offer to acquire CVRx Inc for approximately $300 million, bringing the heart-device specialist into focus for investors. The acquisition highlights the strategic value of CVRx's Barostim device, which treats heart failure and hypertension, and Medtronic's aim to expand its cardiovascular portfolio. The deal provides CVRx with access to Medtronic's global infrastructure and offers liquidity to shareholders, reflecting how larger companies seek innovation from smaller, publicly traded firms.
Number of shareholders of CVRx, Inc. – NASDAQ:CVRX
This article provides details about CVRx, Inc. (NASDAQ: CVRX) within the TradingView platform. It navigates to the financial section of the company's profile. The content indicates that the market is closed and no trades are currently occurring.
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
CVRx, Inc. announced that Humana has issued a Medicare Advantage coverage policy for its Barostim therapy, effective May 1, 2026. This policy marks a significant milestone, expanding access for heart failure patients and validating CVRx's commercial strategy. Humana, a major national health insurance provider, will cover Barostim for patients meeting FDA-approved indications and those enrolled in the BENEFIT-HF trial.
The CVRx, Inc. (NASDAQ:CVRX) First-Quarter Results Are Out And Analysts Have Published New Forecasts
CVRx, Inc. shareholders experienced a 22% drop in share price after the company released its first-quarter results. Revenue of US$15m and a statutory loss of US$0.50 per share were in line with analyst forecasts. Analysts predict revenues of US$65.3m for 2026, with losses holding steady around US$1.95 per share, and the consensus price target remains unchanged at US$11.17, indicating that the business performance is meeting expectations despite the significant share price fall.
CVRx rebounds as Humana issues Medicare policy for Barostim
CVRx shares significantly increased after Humana, a major Medicare Advantage payer, issued a positive coverage policy for the company's Barostim therapy. This policy makes CVRx's Barostim available to Humana's 5.5 million Medicare Advantage members for heart failure treatment. The news is seen as a key step towards broader market adoption and increasing access for patients.
CVRx Inc | 10-Q: Q1 2026 Earnings Report
This document is the 10-Q filing for CVRx Inc, detailing its earnings report for the first quarter of 2026. This financial report provides a comprehensive overview of the company's performance, operations, and financial position during that period.
CVRx Announces Humana Medicare Advantage Coverage Policy for Barostim Therapy
CVRx announced that Humana has issued a Medicare Advantage coverage policy for its Barostim therapy, effective May 1, 2026. This policy marks a significant milestone, expanding access to the heart failure treatment for Humana's 5.2 million Medicare Advantage members across 46 states. The coverage includes patients meeting FDA-approved indications and those in the BENEFIT-HF trial, following previous positive reimbursement developments this year.
Lake Street Maintains CVRx Inc(CVRX.US) With Buy Rating, Maintains Target Price $14
Lake Street has reaffirmed its Buy rating on CVRx Inc (CVRX.US) and maintained its target price of $14. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
